Company Overview and News

 
Jubilant Foodworks Limited - Updates

23h nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.

 
Jubilant Foodworks Limited - Trading Window

2018-04-17 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.

 
Sensex, Nifty clock gains for 9th consecutive session; investors await corporate earnings

2018-04-17 moneycontrol
Bulls continued to have upper hand at Dalal Street for the ninth consecutive session on Tuesday after normal monsoon forecast for June-September period, as investors await corporate earnings. Positive global cues also boosted sentiment.

 
Closing Bell: Sensex ends rangebound session higher; hotels, jewellery, realty stocks rally

2018-04-17 moneycontrol
3:30 pm Market Closing: Benchmark indices managed to end near day's high after volatility throughout the session.

 
Market Update: Nifty Realty outperforms led by Godrej Properties; ICICI, HDFC Bank gain, DHFL most active

2018-04-17 moneycontrol
The Indian equity market was trading on a positive note on Tuesday morning with the Nifty adding 18 points and was trading at 10,546 while the Sensex was up 80 points or 0.23 percent.

 
Market Update: TCS, Wipro shed 1% as CNX IT drags; Power Grid top gainer, Bharti Infratel down 2%

2018-04-17 moneycontrol
The Indian equity market slipped into the red on Tuesday afternoon with the Nifty shedding 23 points and was trading just above the 10,500 mark at 10,505 while the Sensex was down 44 points or 0.13 percent.

 
Market Update: Hindalco up 3% as metal stocks shine, Power Grid top Nifty gainer; Bajaj Electricals jumps 7%

2018-04-17 moneycontrol
The Indian equity market was trading on a positive note on Tuesday morning with the Nifty adding 5 points and was trading at 10,533 while the Sensex was up 19 points.

 
Jubilant Foodworks Limited - Option to submit Standalone/Consolidated Financial Results

2018-04-16 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.

 
Home rental start-up ZiffyHomes acquires rival Nivaasa

2018-04-12 livemint
New Delhi: Home rental start-up ZiffyHomes on Thursday said it has acquired smaller rival Nivaasa, operated by Gurugram-based Accurent Property Management Pvt. Ltd, in an all-cash deal.

 
Market Update: CNX IT zooms 3.7% as TCS, Infosys jumps over 2%; Nifty PSU bank falls 3%; Jubilant Food at new 52-week high

2018-04-12 moneycontrol
The Indian equity market was trading on a positive note on Thursday morning with the Nifty adding 20 points at 10,421 mark while the Sensex was up 51 points or 0.14 percent.

 
Market Update: Infosys jumps 4% ahead of results as Nifty IT zooms 5%; Tata Sponge up 14%; PSU banks drag

2018-04-12 moneycontrol
The Indian equity market was trading on a positive note on Thursday morning with the Nifty adding 37 points at 10,454 mark while the Sensex was up 174 points or 0.51 percent.

 
Jubilant Foodworks Limited - ESOP/ESOS/ESPS

2018-04-10 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.

 
Banks, FMCG, oil stocks lift Sensex 162 pts amid positive global cues; Infosys dips

2018-04-09 moneycontrol
The market extended positive move for the third consecutive session on Monday as the Sensex rallied more than 200 points intraday following positive lead from global stocks after US-China trade war tensions abated.

 
Closing Bell: Sensex rises 162 pts, Nifty ends above 10,350; banks, FMCG lead

2018-04-09 moneycontrol
3:30 pm Market Closing: Benchmark indices closed higher on positive global cues as trade war tensions eased.

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 00B3PRM66